Dual analyte immunoassay for methamphetamine and amphetamine
First Claim
1. In a dual analyte immunoassay for the detection of amphetamine and methamphetamine in a sample, wherein to the sample is added an antibody selective for amphetamine and an antibody selective for methamphetamine, and whereby the presence of amphetamine and/or methamphetamine is determined by measuring the amount of a labelled reagent which remains bound or unbound to such antibodies as a result of competitive displacement by an analyte which may be present in such sample, the improvement comprising utilizing as the labelled reagent an amphetamine of the formula:
- ##STR3## wherein L is a detectable labelling moiety, A is a linkage group capable of physically or chemically binding to L, X is H2, O, S or NH, and n=1-6;
the antibody selective for amphetamine is generated by an immunogen of the formula;
##STR4## and the antibody selective for methamphetamine is generated from an immunogen of the formula;
##STR5## where m and m'"'"' are ±
1 or the same as n independently for the methamphetamine and amphetamine immunogens, and P is a poly (amino acid) having reactive amine groups.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a novel immunoassay for the detection of multiple analytes such as amphetamine and methamphetamine in a single assay of a biological fluid sample. In this assay, a single labelled binding partner is utilized capable of cross reacting at differing sensitivities to antibodies derived from conjugate derivatives of the different analytes such that the presence of the analytes at selected levels of concentration of the analytes singly or in combination can be detected.
-
Citations
5 Claims
-
1. In a dual analyte immunoassay for the detection of amphetamine and methamphetamine in a sample, wherein to the sample is added an antibody selective for amphetamine and an antibody selective for methamphetamine, and whereby the presence of amphetamine and/or methamphetamine is determined by measuring the amount of a labelled reagent which remains bound or unbound to such antibodies as a result of competitive displacement by an analyte which may be present in such sample, the improvement comprising utilizing as the labelled reagent an amphetamine of the formula:
- ##STR3## wherein L is a detectable labelling moiety, A is a linkage group capable of physically or chemically binding to L, X is H2, O, S or NH, and n=1-6;
the antibody selective for amphetamine is generated by an immunogen of the formula;
##STR4## and the antibody selective for methamphetamine is generated from an immunogen of the formula;
##STR5## where m and m'"'"' are ±
1 or the same as n independently for the methamphetamine and amphetamine immunogens, and P is a poly (amino acid) having reactive amine groups. - View Dependent Claims (2, 3, 4, 5)
- ##STR3## wherein L is a detectable labelling moiety, A is a linkage group capable of physically or chemically binding to L, X is H2, O, S or NH, and n=1-6;
Specification
-
- Resources
-
Current AssigneeRoche Diagnostics Operations Incorporated (Roche Holding AG)
-
Original AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
InventorsOrdonez, Kathy P., Salamone, Salvatore J.
-
Primary Examiner(s)CEPERLEY, MARY
-
Application NumberUS08/258,125Time in Patent Office655 DaysField of Search436/534, 436/545, 436/546, 436/816, 435/7.93US Class Current436/534CPC Class CodesG01N 33/53 Immunoassay; Biospecific bi...G01N 33/54306 Solid-phase reaction mechan...G01N 33/946 CNS-stimulants, e.g. cocain...Y10S 436/816 Alkaloids, amphetamines, an...
